Hypertension is the most commonly seen condition in adult primary care practices, affecting one in three American adults over the age of 18, with women and men being nearly equally affected.
Introduction
High blood pressure is the greatest threat to the global burden of disease, contributing to an estimated 9.4 million deaths a year. 1 Cardiovascular disease morbidity and mortality are positively correlated with the degree of elevation of blood pressure, without any evidence of a threshold down to at least 115/75 mm Hg. 2 Hypertension is common, and nearly every clinician in every specialty deals either directly or indirectly with managing it or its consequences. Hypertension obviously exists on a spectrum, with higher elevations of blood pressure conferring greater risk and potentially more severe consequences. Mild hypertension is typically defined as an office systolic blood pressure between 140 and 159 mm Hg or a diastolic pressure between 90 and 99 mm Hg, with neither being 160/100 mm Hg or above. Note that the use of the word "mild" in this article refers to the level of blood pressure and not to its degree of clinical or public health importance. Because most people diagnosed as having hypertension in modern practice have "mild" hypertension, it is important to understand how best to serve these patients. Overall, the quality of the direct evidence for managing mild hypertension is low, but high quality indirect evidence exists. In this article, we review the evidence based diagnosis, non-drug and drug treatment, goals of treatment, and overall strategies for managing patients with mild hypertension.
ABSTRACT
Elevated blood pressure is a common risk factor for cardiovascular disease and affects one in three adults. Blood pressure lowering drugs substantially reduce the risk of stroke, coronary heart disease, heart failure, and premature death, but most clinical trials showing benefits have primarily included patients with moderate to severe hypertension, known cardiovascular disease, or elevated risk of cardiovascular disease. The benefits of treating mild hypertension in patients without cardiovascular disease are less clear, but recent meta-analyses offer some insights. Pooled data from trials that include a large percentage of participants with mild hypertension show significant reductions in stroke, death from cardiovascular disease, and total mortality. Meta-analyses comparing lower blood pressure targets also suggest a benefit of treating patients with mild hypertension, although net benefits are greater for patients at higher absolute levels of cardiovascular disease risk. Before starting drug treatment, most patients should have out-of-office monitoring to confirm hypertension. Lifestyle modifications for reducing blood pressure are appropriate for all patients and may be recommended while delaying drug treatment for those at lower absolute levels of cardiovascular disease risk. Patient level control of blood pressure is supported by home monitoring and by once daily, low cost drug. Control of blood pressure for a population of patients is enhanced by system level interventions such as registries, implementation of evidence based protocols, drug titration visits, and performance metrics.
the auscultatory or oscillometric method. 15 16 An appropriate sized cuff (cuff bladder encircling at least 80% of the arm) should be used to ensure accuracy. 15 Patients should be seated quietly for at least five minutes in a chair with their feet on the floor and arm supported at heart level. Ideally, caffeine and nicotine should not have been ingested within the 30 minutes before measurement.
Given the overall poor sensitivity and specificity of typical office blood pressure measurements for diagnosing hypertension, both the USPSTF and the UK National Institute for Health and Care Excellence (NICE) now recommend using out-of-office blood pressure measurements, ideally 24 hour ambulatory monitoring, to confirm the diagnosis before starting drugs. 12 17 Ambulatory blood pressure monitoring helps to avoid misclassification of people as hypertensive, which reduces unwarranted blood pressure lowering treatment. 12 18 Such misclassification is more prone to occur with blood pressure levels closer to the diagnostic threshold (that is, 140/90 mm Hg). When ambulatory monitoring is not feasible, systematically performed home blood pressure monitoring is an alternative strategy to obtain out-of-office measurements. 12 19 Out-of-office measurements may be especially relevant to patients with mildly elevated office blood pressure readings (that is, possible mild hypertension), for which the probability of white coat hypertension is higher. For example, even among patients with a carefully measured office blood pressure that is elevated, up to 20% have non-elevated ("normal") blood pressure on ambulatory monitoring. 20 Multiple studies show that ambulatory blood pressure better predicts cardiovascular disease outcomes and that the risk of cardiovascular disease among patients with white coat hypertension is low enough to not warrant blood pressure lowering treatment for most. [21] [22] [23] [24] However, data on cardiovascular disease risk among patients with white coat hypertension are conflicting, and risk varies according to several factors, including treatment status. [25] [26] [27] [28] Definition of mild hypertension Hypertension can be classified into one of several categories generally based on office blood pressure levels (table  1) . The blood pressure category into which a patient falls can be used to help to guide treatment. As mentioned earlier, mild hypertension is typically defined as an office systolic blood pressure between 140 and 159 mm Hg or diastolic pressure between 90 and 99 mm Hg, with neither being 160/100 mm Hg or above. 11 It is worth remembering that elevated blood pressure is a risk factor or a sign rather than a disease, and the most practical definition of hypertension itself is that level of blood pressure above which treatment confers appreciable net benefit (that is, does more good than harm).
Overall benefits of treatment
In clinical trials, antihypertensive drug treatment has been associated with 35-40% reductions in incidence of stroke, 20-25% reductions in myocardial infarction, and more than 50% reductions in heart failure, effects that are broadly comparable and highly generalizable across approximately 75% were taking antihypertensive drugs. 6 7 Even so, approximately 47% of patients with hypertension have uncontrolled blood pressure. 6 7 Most uncontrolled hypertension is not in patients who lack clinical visits or are without insurance but occurs among patients who have insurance and are making primary care visits. 8 Of the preventive services clinicians can offer, treatment of hypertension is one of the most beneficial. Among the US population, for example, each 10% increase in treatment of hypertension would prevent 14 000 premature deaths.
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Sources and selection criteria We searched Medline and reference lists from included articles between 1966 and November 2015, with an update to include up to August 2016. Searches were limited to the English language. Our search terms included grade 1 hypertension, mild hypertension, hypertension, hypertension therapy, systematic review, and clinical trial. We included MeSH terms when appropriate and also searched the clinicaltrials.gov and Cochrane databases. We searched for relevant systematic reviews and randomized controlled clinical trials and prioritized those that were large, high quality, and most recent. We excluded case reports, case series, and observational studies. Both authors contributed to searching the literature and assessing quality of the evidence. The review is intended for a predominantly US audience, so preference was given to US guidelines, although we also included European guidelines for completeness and comparison.
Diagnosis of hypertension
The United States Preventive Services Task Force (USP-STF) recommends screening all adults over 18 years old for hypertension. 10 Whereas the USPSTF previously made no recommendation as to screening interval, the Joint National Committee (JNC)-7 guidelines recommended screening adults every two years if blood pressure was recorded as less than 120/80 mm Hg and every year for systolic blood pressure 120-139 mm Hg or diastolic pressure 80-90 mm Hg. 11 Recently, the USPSTF published recommendations for annual screening of adults 40 years and older and those at increased risk for high blood pressure. 12 People deemed to be at increased risk include those who have "high normal" blood pressure (130-139/85-89 mm Hg), are overweight or obese, or are African-American. According to the USPSTF recommendation, adults aged 18-39 years with "normal" BP (<130/85 mm Hg) who do not have other risk factors should be rescreened every three to five years. 12 13 Diagnosis of hypertension using office blood pressure measurements should be based on at least two separately recorded elevated blood pressure measurements. An elevated blood pressure reading noted at an initial visit should be confirmed at a follow-up visit, preferably with at least two blood pressure measurements separated by at least one minute. [11] [12] [13] [14] [15] In a patient with a markedly elevated office blood pressure reading who already has hypertension related target organ damage, the diagnosis may be made without follow-up readings.
11 Blood pressure should be recorded in a standardized fashion using at a diastolic pressure of 90 mm Hg or above and treat to a goal of below 90 mm Hg. 32 In the population aged 18 years or over with chronic kidney disease or diabetes, the recommendation is to start drug treatment at a systolic pressure of 140 mm Hg or above or a diastolic pressure of 90 mm Hg or above and treat to a goal of below 140/90 mm Hg. 32 These recommendations were purported to be made with the highest level of evidence based on high quality randomized controlled trials and meta-analyses available at the time of the literature review. However, even among the panel members, controversy surrounded the recommendations, with some members noting that the evidence supporting the increase in the systolic blood pressure target to 150 mm Hg in people 60 years or older was insufficient and inconsistent with the evidence used to support the target blood pressure of 140 mm Hg in patients younger than 60 years. 33 The landmark Systolic Blood Pressure Intervention Trial (SPRINT) published in 2015 offers insights into blood pressure treatment goals despite not being a trial of treating mild hypertension. 34 Investigators randomly assigned 9361 people aged 50 and older with a systolic blood pressure of 130 mm Hg or above and either established cardiovascular disease (20% of the participants) or an increased risk of cardiovascular disease (61% of participants had a 10 year cardiovascular disease risk ≥15%), but without diabetes, to a systolic blood pressure target of below 120 mm Hg (intensive treatment) or a target of below 140 mm Hg (standard treatment). 34 The protocol encouraged use of evidenced based drug classes but did not mandate use of certain drugs. Drugs were adjusted monthly in each arm to the predetermined blood pressure target. At randomization, the recommendation was to begin with two or three drugs, using a combination of a thiazide-type diuretic (preferably chlorthalidone), and/or an angiotension converting enzyme inhibitor or angiotensin receptor blocker (but not both), and/or a calcium channel blocker (preferably amlodipine). The primary composite outcome was myocardial infarction, other acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes. At baseline, most (91%) participants were already on blood pressure lowering treatment, and mean blood pressure was 140/78 mm Hg with systolic pressure below 145 mm Hg in 66%.
At one year follow-up, the mean systolic blood pressure was 121 mm Hg in the intensive treatment group and 136 mm Hg in the standard treatment group. Given a significantly lower rate of the primary composite outcome in the intensive treatment group compared with the standard treatment group (1.65% v 2.19% per year; hazard ratio 0.75, 95% confidence interval 0.64 to 0.89), the trial was stopped early after a median follow-up of approximately 3.3 years. Notably, all cause mortality was also 27% lower in the intensive treatment group. Although overall rates of side effects were similar between treatment groups, the rates of some adverse events (hypotension (2.4% v 1.4%), syncope (2.3% v 1.7%), electrolyte abnormalities (3.1% v 2.3%), and acute kidney injury (4.1% v 2.5%)) were higher in the intensive treatment group. diverse patient groups. 29 These data support treating patients with drugs to reduce blood pressure in order to prevent the morbidity and mortality associated with hypertension. Notably, the antihypertensive clinical trials either enrolled patients with established cardiovascular disease (such that treatment with blood pressure lowering drugs would represent secondary prevention) or enrolled patients with moderately severe levels of blood pressure and/or higher levels of cardiovascular risk. Several of the secondary prevention trials also showed clear benefits in non-hypertensive patients. No trials have examined primary prevention of cardiovascular disease events among patients exclusively with mild hypertension. Given that thousands of patients would need to be followed for many years to accrue enough events to draw conclusions about mortality, it is unlikely that a placebo controlled trial assessing treatment of mild hypertension will ever be done.
Given the relatively low risk of a cardiovascular disease event among patients with mild hypertension, trials with large sample sizes and long study durations are needed. Such trials have not been done. The benefits of blood pressure reduction in people with mild hypertension, especially those with low overall cardiovascular disease risk, are therefore not clear. This lack of clarity is problematic given that about half of the people treated with antihypertensive drugs are considered to have mild hypertension. 30 31 Furthermore, when patients with mild hypertension have been included in clinical trials, the evaluation of these treatments in this particular subgroup is often not analyzed or not presented. Most antihypertensive drugs have been evaluated for secondary prevention in patients with hypertension, not exclusively in those with mild hypertension for primary prevention. Therefore, the benefits of antihypertensive treatments for secondary prevention are often extrapolated to primary prevention.
The panel members appointed to the JNC-8 provided an evidence based update to blood pressure treatment goals in 2014. 32 The report states that, in the general population aged 60 years and over, drug treatment should be started to lower blood pressure at a systolic pressure of at least 150 mm Hg or a diastolic pressure of at least 90 mm Hg, with treatment to a goal systolic pressure below 150 mm Hg and a goal diastolic pressure below 90 mm Hg. 28 For patients under 60 years of age, on the basis of expert opinion, the recommendation was to start treatment with a systolic blood pressure of 140 mm Hg or above and treat to a goal of below 140 mm Hg, and grade A recommendation was to start drug treatment to lower blood pressure Adapted from Joint National Committee-7 report.
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*BP lowering drugs may not be indicated for all; the evidence for this group is limited reviews included randomized clinical trials of at least one year's duration that enrolled adult patients of whom at least 80% had mild hypertension and no overt cardiovascular disease. Cardiovascular disease was defined as myocardial infarction, angina pectoris, coronary bypass surgery, percutaneous coronary intervention, stroke, transient ischemic attack, carotid surgery, peripheral arterial surgery, intermittent claudication, or renal failure. In each included trial, the active arm, which included an antihypertensive drug given as monotherapy or additional therapy provided in a stepwise approach, was compared with no active treatment or another regimen. The first review, published in 2012, included the primary outcomes of total mortality and total cardiovascular events (total stroke, myocardial infarction, congestive heart failure) and secondary outcomes of total stroke (fatal and non-fatal strokes), total coronary heart disease (fatal and non-fatal myocardial infarction, sudden death), and withdrawals due to adverse effects. 37 The second review, published in 2015, incorporated total cardiovascular events, including total stroke, total coronary events (non-fatal myocardial infarction and death from coronary heart disease), heart failure (causing death or resulting in hospital admission), or cardiovascular death, as well as each outcome individually and total deaths. 38 Tables  3 and 4 summarize the clinical trials included in both systematic reviews.
The first review included four trials, [39] [40] [41] [42] published from 1946 to 2011, consisting of 8912 participants. Individual patient data were available from three trials (ANBP, 39 MRC, 40 SHEP 41 ), and only patients who met the above stated criteria at baseline were included. The VA-NHLBI trial was also included as less than 20% of the participants had moderately elevated blood pressure. 42 Among SPRINT participants, the concluding mean number of blood pressure lowering drug in the intensive treatment group was 2.8 compared with 1.8 in the standard treatment group. About half the participants in the intensive group did not achieve systolic blood pressure below 120 mm Hg, which probably reflects the difficulty of getting to this blood pressure level as well as some caution on the part of the clinicians. It is also important to note that office BP readings were taken with participants properly positioned using an automatic monitor that was preset to wait for five minutes before measurement and to automatically take an average of three consecutive readings without an observer present (automated office blood pressure). Such a strategy helps to mitigate the white coat effect. 35 In terms of generalizability, a National Healthcare and Nutrition Examination Survey (NHANES) analysis suggests that about 16.7% of hypertensive patients would meet the SPRINT qualifying criteria. 36 Such patients are more likely to be older, male, and non-Hispanic white. 36 Overall, the trial showed that for certain non-diabetic patients with established cardiovascular disease or at increased risk, a lower blood pressure target-when blood pressure is carefully measured-reduces cardiovascular disease events. However, these findings may not be applicable to a large proportion of patients with mild hypertension in primary prevention.
Drug treatment of mild hypertension Meta-analyses of mild hypertension trials
Two recent high quality systematic reviews and metaanalyses were conducted specifically to evaluate the benefit of blood pressure reduction in patients with mild hypertension (table 2) . 37 38 Both of these comprehensive CHD=coronary heart disease; CHF=congestive heart failure; CVD=cardiovascular disease. 37 Furthermore, treatment compared with placebo did not reduce total coronary heart disease (relative risk 1.12, 0.80 to 1.57) or total cardiovascular events (0.97, 0.72 to 1.32) in these analyses. 37 Data on withdrawals from treatment and side effects in the subgroup of mild hypertensive patients are limited. In the first review, withdrawals due to adverse effects were reported only for the MRC trials and not specifically from the mild hypertensive subgroup (table 3) . Therefore, the withdrawal rates due to adverse effects were calculated for the entire study population and showed a relative risk of 4.80 (4.14 to 5.57) and an absolute risk increase of 8.9%. The Veterans Administration-National Heart, Lung, and Blood Institute (VA-NHLBI) trial reported any side effect at a rate of 1642/508 in the treatment group and 920/504 in the placebo group. Chemical abnormalities occurred more often in the treatment group (216 versus 15 in the control group). Given that the MRC trial used higher than the currently recommended dose of a thiazide and a β blocker, which is no longer recommended as first line therapy, withdrawals in practice today may not be as high as those seen in the MRC trial.
In February 2015 the second systematic review was completed applying the same protocol used for the first review but limited to May 2011 to June 2014 in order to update the evidence. 38 Individual patient data from 10 Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) trials and aggregate data from three other trials were extracted for 15 266 patients with stage 1 hypertension without pre-existing cardiovascular disease (table 4) . Of note, most of the 6361 patients from BPLTTC trials had diabetes. Their mean blood pressure was 146/84 mm Hg. Limited baseline demographics are available for non-BPLTTC studies, but no patients had diabetes or previous antihypertensive therapy.
One potential limitation of the 2012 review is that most patients in the included trials were receiving agents such as β blockers that are no longer recommended as first line treatment for uncomplicated hypertension. 37 In the 2015 review, 38 this limitation was mitigated by including trials of angiotensin converting enzyme inhibitors versus placebo, calcium channel blockers versus placebo, diuretics versus placebo, and more intensive versus less intensive blood pressure lowering regimens.
Overall, treatment with antihypertensive drugs showed beneficial effects on all outcomes. Pooled odds ratios were 0.86 (95% confidence interval 0.74 to 1.01) for total cardiovascular events, 0.72 (0.55 to 0.94) for strokes, 0.91 (0.74 to 1.12) for coronary events, 0.80 (0.57 to 1.12) for heart failure, 0.75 (0.57 to 0.98) for cardiovascular deaths, and 0.78 (0.67 to 0.92) for total deaths. Pooling the results from these trials showed that antihypertensive treatment in patients with mild hypertension likely prevents cardiovascular events, particularly stroke and mortality. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] Withdrawals were equally common in the active (337 of 1582) and control (357 of 1583) groups. However, 14 (10) 445 (16) 41 (16) 27 (10) 302 (18) 16 (29) 61 (29) 2 ( (100) 261 (100) 272 (100) 1998 (100) 5 (9) 10 (5) 3 (19) 453 (100) 0 (0)
No (%) previous antihypertensive therapy 78 (37) 51 (36) 1907 (70) 261 (100) 272 (100) 911 (46) 18 ( 147 (6) 148 (6) 147 (6) 148 (6) 145 (6) 146 (9) 147 (6) 141 (9) 145 ( 85 (3) 82 (8) 87 (6) 87 (6) 82 (7) 85 (9) 84 (7) 81 (8) 93 ( benefit (that is, the benefits exceed potential harms). For patients at low overall cardiovascular disease risk (which includes many younger people), however, a proportionally equivalent relative risk reduction (for example, 20%) for a given outcome may not offer an appropriate balance of potential benefit versus potential harm. For example, a 40 year old African-American woman (nonsmoker) with an office blood pressure of 144/72 mm Hg who has no other risk factors has an estimated 10 year risk of 1-2% for heart disease or stroke (calculator at www.cvriskcalculator.com). Reducing this risk by 20% with blood pressure lowering treatment would confer an absolute risk reduction of only 0.2-0.4%. Thus, for patients with mild hypertension at low overall risk, the potential downsides of drug treatment may make it not worthwhile to them. Another reason that a solely threshold based approach may be suboptimal is that patients with "borderline" blood pressure levels or mild hypertension may not be offered blood pressure lowering drugs despite having an overall high cardiovascular disease risk. Consider a 65 year old man with a blood pressure of 135/75 mm Hg, diabetes, and dyslipidemia, whose 10 year risk for a cardiovascular disease event is 35%. Blood pressure lowering drugs would offer a substantial absolute risk reduction (of about 7%), yet on the basis of solely a blood pressure threshold approach he would not qualify for treatment by many guidelines.
In an analysis of data from two large cohort studies, among US adults 45-64 years of age at baseline not treated for hypertension (n=14 856), 56% of excess cardiovascular disease events over the following 10 years occurred in people with systolic blood pressure that was below 140 mm Hg (and hence not eligible for treatment by blood pressure level). 54 Also, a 10 year predicted cardiovascular disease risk of 7.5% or higher had greater sensitivity and specificity than a systolic blood pressure level treatment threshold. Use of a risk based approach might offer a better balance of benefits and risks as well as distribute blood pressure treatment resources more equitably and rationally. 31 
Choice of drug
When the decision is made to treat mild hypertension with drugs, several first line therapies are available ( fig  1) . These agents are considered the most evidence based therapies for managing hypertension. 17 32 The JNC-8 guidelines recommend initial therapy with a thiazidetype diuretic, calcium channel blocker, angiotensin converting enzyme inhibitor, or angiotensin receptor blocker in the general non-black population and either a thiazidewithdrawals due to adverse effects were more common in the treatment group than in the placebo group in the ADVANCE trial, the only study to report these data. Reasons for withdrawal were defined as those due to cough, dizziness, hypotension, or a serious adverse event.
Meta-analyses of trials with stratification by baseline blood pressure level In addition to the systematic reviews that pool data from the randomized trials that predominantly enrolled patients with mild hypertension, others have sought to pool together all (or nearly all) antihypertensive clinical trials with endpoints of cardiovascular disease or death, and in their meta-analyses provide results stratified according to baseline or pretreatment blood pressure level (table 5) . 52 53 In one such analysis, in which seven trials were included for the stratified analysis (out of total of 147 trials), patients with pretreatment systolic blood pressure of 140-149 mm Hg had a relative risk reduction of 0.15 (95% confidence interval 0.06 to 0.24) for coronary heart disease events when treated with blood pressure lowering drugs. 52 Pooled, stratified results from eight trials with this level of pretreatment systolic blood pressure showed a relative risk reduction of 0.23 (0.05 to 0.28) for strokes. Overall, no significant differences existed in the pooled risk reduction estimates based on pretreatment systolic or diastolic blood pressure level, even down to a level of 110/70 mm Hg. When results were stratified by primary versus secondary prevention, no significant difference were seen in the risk reductions.
Another recent systematic review published in 2015 identified 123 trials of blood pressure lowering treatment and also found no threshold below which therapy no longer seemed to confer risk reduction. 53 Among 4365 patients whose baseline systolic blood pressure was 140-149 mm Hg pooled from seven of the trials, blood pressure lowering therapy reduced risk for major cardiovascular disease events by 21% (13% to 28%) for each 10 mm Hg reduction in systolic pressure. 53 No significant difference in this risk reduction was seen across categories of baseline blood pressure level.
Blood pressure level versus global risk
When managing patients' blood pressure, the prevailing clinical approach is to diagnose and offer treatment on the basis of a threshold blood pressure level (for example, average office blood pressure >140/90 mm Hg). For patients with moderate to markedly elevated blood pressure (for example, >160/100 mm Hg) or who already have signs of target organ damage (such as left ventricular hypertrophy), such an approach offers sufficient net Trials included in the stratified analyses were a small subset of the total trials BP=blood pressure; CHD=coronary heart disease; CVD=cardiovascular disease; RCT=randomized controlled trial.
Thiazide diuretics can cause hyperuricemia, hyperglycemia, hyponatremia, and hypokalemia. The incidence and severity of these metabolic complications is low with use of low dose thiazide therapy. [59] [60] [61] [62] Despite the risk of adverse effects, thiazide diuretics are thus relatively safe and well tolerated. 63 Serum electrolytes should be checked periodically during therapy, and supplementation with potassium can be implemented if needed. Consider an alternate agent to a calcium channel blocker if a patient develops edema or if there is evidence of heart failure or a high risk of heart failure. 17 64 Within one to two weeks after starting an angiotensin converting enzyme inhibitor, and periodically thereafter, renal function and serum potassium should be reassessed. 65 An increase of up to 30% in serum creatinine is within acceptable limits to continue therapy. 65 66 β blockers are not recommended for initial treatment of uncomplicated hypertension owing to the conflicting evidence on their benefit. In one trial, patients treated with a β blocker had higher rates of cardiovascular disease death, myocardial infarction, and stroke compared with those receiving an angiotensin receptor blocker. 67 α blockers are also not recommended because in the ALL-HAT trial, treatment with doxazosin resulted in worse outcomes leading to early termination of the study arm. 55 More evidence is needed on the place in therapy for central α2-adrenergic agonists, peripherally acting adrenergic antagonists, mineralocorticoid receptor antagonists, loop diuretics, and direct vasodilators.
Lifestyle modifications
The patients we involved in crafting this review (see box) all emphasized their desire to at least try lifestyle modifications to lower their blood pressure, especially if it was only "mildly" elevated. Several lifestyle modifications have been shown to reduce blood pressure and are recommended as part of the management of all patients with hypertension. 11 68 These recommendations include the Dietary Approaches to Stop Hypertension (DASH) eating plan, 69 reduced dietary sodium intake, [70] [71] [72] exercise, 72 73 reduced alcohol intake, 74 75 and weight loss if overweight 76 77 (fig 2) . The DASH diet is rich in potassium, magnesium, and calcium obtained from fruits, vegetables, and low fat dairy products. Randomized trials have shown a significant decrease in blood pressure for as long as 18 months in patients adhering to the DASH diet. 78 79 Even though patients may not completely adhere, partial dietary changes may still give a graduated response. Unfortunately, the reality is that many patients are unable to start and sustain behavioral change.
Adoption of multiple lifestyle recommendations simultaneously may be sufficient to control mild hypertension. For example, in the PREMIER trial, 810 adults with mild (stage 1) hypertension not taking antihypertensive drugs were randomized to advice only (control); weight loss, increased physical activity, and reduced sodium and alcohol intake; or the latter plus the DASH eating plan. 79 80 The primary outcome was change in systolic blood pressure at six months. Compared with the control group, mean systolic blood pressure decreased by 3.7 mm Hg for members of the multiple type diuretic or a calcium channel blocker in the general black population. 32 Among patients with chronic kidney disease, an angiotensin converting enzyme inhibitor or angiotensin receptor blocker is recommended first line. 32 Before the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attacks Trial (ALLHAT), 55 56 published in 2002, antihypertensive treatment had shown an ability to reduce morbidity and mortality in comparison with placebo, [57] [58] [59] but more evidence was needed to better elucidate the optimal choice of initial antihypertensive drug. The ALLHAT trial enrolled 33 357 patients with at least one coronary heart disease risk factor and directly compared the effects of chlorthalidone 12.5 to 25 mg/ day, amlodipine 2.5 to 10 mg daily, or lisinopril 10 to 40 mg daily over a mean study duration of 4.9 years. The study showed no difference between treatment arms with respect to the primary outcome of combined fatal coronary heart disease or myocardial infarction or secondary outcomes of all cause mortality, stroke, and combined coronary heart disease. However, a higher rate of heart failure occurred in patients receiving calcium channel blockers compared with angiotensin converting enzyme inhibitors or chlorthalidone. Chlorthalidone was shown to be more effective than an angiotensin converting enzyme inhibitor in the black population. Therefore, a calcium channel blocker or thiazide-type diuretic is initially preferred over an angiotensin converting enzyme inhibitor for black patients. 
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System based strategies for blood pressure control Although attaining control of blood pressure among patients with mild hypertension might seem inherently as if it should be "easier" than for more severe hypertension, it is nonetheless challenging. Patients' ability to adopt and adhere to lifestyle recommendations often depends on far more than brief clinical advice. When drugs are prescribed, patients must actually start and continue taking them. Evidence shows that initiation of and persistence with drug treatment are suboptimal. [82] [83] [84] [85] Mild hypertension, in particular, may be a factor associated with failure to persist with blood pressure lowering treatment. 85 In addition to patient related factors, some clinical factors also impede achievement of blood pressure control, such as competing demands and time pressures. 86 Many quality improvement strategies for blood pressure control have been described, the most successful of which include a comprehensive system level approach with incorporation of population management principles. [87] [88] [89] At Kaiser-Permanente Northern California, for example, the use of a comprehensive multi-component hypertension quality improvement program (fig 3) led to a dramatic 36.8% improvement in hypertension control between 2001 and 2009, with more than 80% of hypertensive patients having controlled blood pressure. 89 lifestyle change group (P<0.001) and 4.3 mm Hg for the multiple lifestyle change plus DASH group (P<0.001). The prevalence of hypertension decreased from 38% to 12% in the multiple lifestyle change plus DASH group (P<0.001) compared with a decrease to 26% in the advice only group. Of course, the exclusion criteria and 89 ACE=angiotensin converting enzyme inclusion of several classes of drugs as first line treatment options. A potential weakness is that interpretation of the evidence may vary among guideline panelists. 33 Nevertheless, the guideline seems appropriate for hypertension care in the US.
The most recent UK NICE guidelines recommend offering antihypertensive treatment to patients under 80 years old with stage 1 hypertension if they have established cardiovascular disease, diabetes, renal disease, or target organ damage. 17 They also recommend offering treatment to patients if their 10 year cardiovascular disease risk is 20% or greater. For patients with mild hypertension at lower risk or without target organ damage, renal disease, or diabetes, the guidelines recommend basing the decision on a more detailed assessment of target organ damage.
European Society of Hypertension guidelines note that the evidence for treating patients with mild hypertension is limited but that delaying treatment increases total risk. 90 The guidelines recommend starting blood pressure lowering treatment, even among patients at lower risk levels, if a reasonable period of lifestyle modifications is not effective.
Conclusions
Management of patients with no established cardiovascular disease with blood pressure categorized as mild hypertension should begin with lifestyle recommendations. For patients at low overall risk, delaying drug therapy may be reasonable, especially if blood pressure reduction is achieved with lifestyle modifications such as weight loss, exercise, or changes in diet. For patients with no target organ damage or at low risk, elevated blood pressure status should be confirmed by out-of-office monitoring before blood pressure lowering treatment is started (fig 4) . Given the low quality evidence available for treatment of mild hypertension, it is important to consider the cost of treatment, the pill burden, and the potential benefit and side effects when making a shared decision with patients.
Among patients with target organ damage or high overall cardiovascular disease risk, drug management should be recommended and, on the basis of SPRINT, consideration should be given to targeting a lower blood pressure goal (<120/80 mm Hg) if blood pressure can be assessed using automated office blood pressure with careful attention to side effects. Among patients with diabetes
Guidelines
The US guideline by panel members appointed to JNC-8 issued a strong (grade A) recommendation to treat patients aged 60 years or older at a systolic blood pressure of 150 mm Hg or above or diastolic pressure 90 mm Hg or above (that is, the upper range of mild hypertension). 32 Such patients are of course at increased risk of cardiovascular disease by virtue of their age. For younger patients aged 30-59 years, a strong recommendation was made for treating on the basis of a diastolic pressure of 90 mm Hg or above. The guideline also recommends treating patients aged under 60 years when systolic pressure is 140 mm Hg or above, but this recommendation was based on expert opinion. Major strengths of the JNC-8 guideline are its reliance on high quality evidence and its 
PATIENT INVOLVEMENT
We asked several patients with mild hypertension to offer their perspective by reading this review and responding to four questions: 1 Does the article cover outcomes that you as a patient feel are important? 2 Does the strategy of lifestyle modifications first, if at low risk, followed by medications as risk increases, resonate with you? 3 How difficult is it to follow lifestyle recommendations for hypertension? 4 What other research questions about mild hypertension would you as a patient like answered? All patients who offered feedback noted that the outcomes are the most important ones they could think of (for example, strokes, heart attacks, deaths). Patients were very much in favor of clinicians discussing lifestyle modifications and "giving [them] a chance to work on…" their blood pressure if their overall risk was judged to be low. Some wanted to try lifestyle modifications alone even if their risk is deemed to be high. They all noted, however, that it is not easy to actually make the lifestyle changes, struggling particularly with diet, exercise, and weight loss. Once a decision is made to begin blood pressure lowering drugs, evidence based strategies for helping patients to achieve goal blood pressure include systematic use of home monitoring and pharmacist assisted titration of drugs. 91 92 Use of low cost, once daily drugs (including fixed dose combination pills as needed) will enhance adherence. 93 Contributors: Both authors contributed to the planning, organizing, and writing of this manuscript. Both authors searched the literature and appraised the evidence. AJV is the guarantor.
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